Tamara Brown, MD
Internal Medicine · Atlanta, GANPI 1174571715
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 257 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,354 and has fallen 85.5% since, to $197 in 2025.
Across 257 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$789
- AstraZeneca$625
- Boehringer Ingelheim$569
- Lilly USA, LLC$333
- Johnson & Johnson$224
- Sanofi-aventis U.S. LLC$210
- plus $1K from 26 others
Across 9 payments — averaging $11,498 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$103K
What the payments were for
- Food & beverage$3,96698%
- Education$962%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 72 | $789 |
| AstraZeneca | 37 | $625 |
| Boehringer Ingelheim | 32 | $569 |
| Lilly USA, LLC | 19 | $333 |
| Johnson & Johnson | 19 | $224 |
| Sanofi-aventis U.S. LLC | 11 | $210 |
| Abbott | 8 | $202 |
| Medtronic | 1 | $138 |
| Sunovion Pharmaceuticals Inc. | 9 | $119 |
| AbbVie(2 entities) | 7 | $112 |
| Arbor Pharmaceuticals, Inc. | 6 | $90 |
| Merck | 6 | $83 |
| Amgen(2 entities) | 3 | $66 |
| Astellas Pharma US Inc | 4 | $65 |
| Sanofi Pasteur Inc. | 2 | $60 |
| Bayer | 2 | $38 |
| Nalu Medical, Inc. | 1 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Gilead | 2 | $28 |
| Pfizer | 2 | $28 |
| Idorsia Pharmaceuticals US Inc | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Eisai Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $22 |
| Corcept Therapeutics | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Shield Therapeutics Inc | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Novartis | 1 | $14 |
| Hologic Sales And Service, LLC | 1 | $14 |
| Ironwood Pharmaceuticals, Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,062 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 108 | $171,849 |
| JardianceEmpagliflozin | 100 | $102,577 |
| FarxigaDapagliflozin Propanediol | 96 | $85,476 |
| TrulicityDulaglutide | 34 | $46,038 |
| GlyxambiEmpagliflozin/Linagliptin | 42 | $41,298 |
| XareltoRivaroxaban | 23 | $35,497 |
| JanuviaSitagliptin Phosphate | 41 | $32,316 |
| EliquisApixaban | 29 | $22,699 |
| SynjardyEmpagliflozin/Metformin Hcl | 13 | $20,428 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $19,342 |
| TradjentaLinagliptin | 18 | $15,159 |
| MyrbetriqMirabegron | 27 | $13,453 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $12,648 |
| RybelsusSemaglutide | 12 | $11,306 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $9,466 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi, Synjardy, Tradjenta, Stiolto Respimat | $569 | $187,892189 claims |
| Novo NordiskOzempic, Rybelsus | $789 | $183,155120 claims |
| AstraZenecaFarxiga, Symbicort | $625 | $87,733107 claims |
| Lilly USA, LLCTrulicity | $333 | $46,03834 claims |
| Johnson & JohnsonXarelto | $224 | $35,49723 claims |
| MerckJanuvia | $83 | $32,31641 claims |
| PfizerEliquis | $28 | $22,69929 claims |
| Astellas Pharma US IncMyrbetriq | $65 | $13,45327 claims |
| AbbVieSynthroid | $112 | $2,35929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Atlanta
- Tracey HenryAtlanta$305K
- Scott ParryAtlanta$162K
- Jennifer GilliganAtlanta$162K
- Tanna LimAtlanta$88K
- Sally IwamotoAtlanta$60K
- Antoine TrammellAtlanta$33K
- Samuel AdamsAtlanta$30K
- Jamal HajjariAtlanta$29K
- Carlos SaldanaAtlanta$25K
- Michael HicksonAtlanta$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.